Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML

Yan Yan, MD, Natalia C Colorado, MD, Shelly Lensing, MS, Delli R Robinson, Nicholas J Baltz, Daohong Zhou, MD, Peter Dean Emanuel, MD, Y. Lucy Liu, MD PhD

Blood (2016) 128 (22): 1550.

https://doi.org/10.1182/blood.V128.22.1550.1550

Published: 2016

Journal Articles

JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency

Nicholas J Baltz, Natalia C Colorado, MD, Yan Yan, MD, Shelly Lensing, MS, Delli Robinson, BA, Michele H. Cottler-Fox, MD, Jason E Farrar, MD, Peter Dean Emanuel, MD, Y. Lucy Liu, MD PhD

Blood (2016) 128 (22): 5899.

https://doi.org/10.1182/blood.V128.22.5899.5899

Published: 2016

Journal Articles

Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States

Nishi Shah, Appalanaidu Sasapu, MD MS, Shebli Atrash, MD, Joshi P Krishna, MD, Laura F Hutchins, MD, Peter Dean Emanuel, MD, Yogesh Jethava, MD

Blood (2016) 128 (22): 4782.

https://doi.org/10.1182/blood.V128.22.4782.4782

Published: 2016

Journal Articles

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Varinder Kaur, MD, Al-Ola Abdallah, MD, Arjun Swami, MD, Shebli Atrash, Daisy V. Alapat, MD, Zhifu Xiang, MD, Pooja Motwani, MD, Fade Mahmoud, MD, Issam Makhoul, MD, Peter Dean Emanuel, MD

Blood (2015) 126 (23): 5019.

https://doi.org/10.1182/blood.V126.23.5019.5019

Published: 2015

Journal Articles

Restoring Cell Responsiveness to GM-CSF and IL-3 by PTEN Is Via Controlling the Regulation of Egr-1 In TF-1a Cell Line

Y. Lucy Liu, MD, PhD, Priyangi Malaviarachchi, Peter Dean Emanuel, MD

Blood (2010) 116 (21): 2504.

https://doi.org/10.1182/blood.V116.21.2504.2504

Published: 2010

Journal Articles

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Priyangi A Malaviarachchi, BS, Shelly Y. Lensing, MS, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2009) 114 (22): 2604.

https://doi.org/10.1182/blood.V114.22.2604.2604

Published: 2009

Journal Articles

Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.

Sophie Archambeault, Ayami Yoshimi, MD, Christian Kratz, MD, Miriam Reising, Alexandra Fischer, Peter Noellke, PhD, Franco Locatelli, MD, Petr Sedlacek, MD, Christian Flotho, MD, Marco Zecca, MD, Peter Dean Emanuel, MD, Robert Castleberry, MD, Charlotte Marie Niemeyer, MD, Peter Bader, MD, Mignon Loh, MD

Blood (2006) 108 (11): 2681.

https://doi.org/10.1182/blood.V108.11.2681.2681

Published: 2006

Journal Articles

Decitabine, a Potential Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Peter Dean Emanuel, MD, Robert P. Castleberry, MD

Blood (2005) 106 (11): 2516.

https://doi.org/10.1182/blood.V106.11.2516.2516

Published: 2005

Journal Articles

.

Peter Dean Emanuel, MD, Zhuo Wang, PhD, Danying Cai, PhD, Mary R. Stofega, PhD, James G. Keck, PhD, Zeev Estrov, MD, Gail L. Brown, MD, Jose L. Ochoa-Bayona, MD, Natalie Callander, MD

Blood (2004) 104 (11): 2372.

https://doi.org/10.1182/blood.V104.11.2372.2372

Published: 2004

Journal Articles

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2004) 104 (11): 2378.

https://doi.org/10.1182/blood.V104.11.2378.2378

Published: 2004

Journal Articles

Evidence for PTEN Deficiency in Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Likang Xu, MD, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2004) 104 (11): 3428.

https://doi.org/10.1182/blood.V104.11.3428.3428

Published: 2004

NARROW

The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML

JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency

Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Restoring Cell Responsiveness to GM-CSF and IL-3 by PTEN Is Via Controlling the Regulation of Egr-1 In TF-1a Cell Line

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.

Decitabine, a Potential Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

.

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Evidence for PTEN Deficiency in Juvenile Myelomonocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only